Sartorius completes acquisition of Albumedix

The life science group Sartorius, through its French listed subgroup Sartorius Stedim Biotech, has successfully closed the acquisition of Albumedix Ltd. as of September 30, 2022. Albumedix is a leader in the field of recombinant albumin-based solutions and based in Nottingham, UK.

This press release contains forward-looking statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius assumes no liability for updating such statements in light of new information or future events. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version.

< | >